KO vs LLY: Which Is the Better Buy?
Side-by-side comparison of The Coca-Cola Company and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
The Coca-Cola Company · Consumer Defensive
$78.19
-7.8% upside to fair value
Grade D
High Quality
VS
Eli Lilly and Company · Healthcare
$934.34
+98.6% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+98.6%).
KO trades at a lower forward P/E
(24.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
KO |
LLY |
| Current Price |
$78.19 |
$934.34 |
| Fair Value Estimate |
$72.12 |
$1,855.91 |
| Upside to Fair Value |
-7.8%
|
+98.6%
|
| Market Cap |
$336.5B |
$882.8B |
| Forward P/E |
24.6x
|
33.1x
|
| EV / EBITDA |
19.9x
|
27.9x
|
| Price / Sales |
6.8x
|
12.2x
|
| Price / FCF |
26.8x
|
65.0x
|
| Revenue Growth YoY |
+12.1%
|
+55.5%
|
| Gross Margin |
61.7%
|
82.7%
|
| Operating Margin |
29.3%
|
46.3%
|
| Return on Equity |
43.6%
|
101.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.73%
|
1.54%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
The Coca-Cola Company is a leading global beverage company specializing in non-alcoholic drinks with a diversified portfolio including sparkling soft drinks, juices, water, coffee, and energy beverages. The business quality is high due to its durable brand moat, consistent earnings growth, and strong operational efficiency, reflected in a 43.6% return on equity and 12.1% revenue growth in the mos…
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Accumulation Zones
| Metric |
KO |
LLY |
| Zone Low |
$54.09 |
$1,391.93 |
| Zone High |
$61.30 |
$1,577.52 |
| In Buy Zone? |
No
|
Yes
|